- Jordi Mones, MD, PhD, to present the first direct-to-Phase 2 randomized, controlled trial data on sonpiretigene isteparvovec optogenetic therapy in macular degeneration
- Benjamin Bakall, MD, PhD, to present 4-year REMAIN extension study data on lasting vision improvement with MCO-010 in retinitis pigmentosa
- Samarendra Mohanty, PhD, Co-Founder, President and Chief Scientific Officer, to deliver a company presentation at the Retina Forum 2026 in Ophthalmology Futures Forums
- Samuel Barone, MD, Chief Medical Officer, to participate in a panel on GA and Intermediate AMD at the Retina Forum 2026 in Ophthalmology Futures Forums
ダラス, Sept. 23, 2026 — ナノスコープ・セラピューティクス, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Jordi Mones, MD, PhD, and Benjamin Bakall, MD, PhD, will present data from Nanoscope’s geographic atrophies and retinitis pigmentosa programs at the 26番目 ユーレティナ会議, taking place October 1-4, 2026, at the VIECON – Vienna Congress & Convention Center in Vienna. The Company also announced that Samarendra Mohanty, Co-Founder, President, and Chief Scientific Officer, and Samuel Barone, the Chief Medical Officer, will deliver a company presentation at the Retina Forum 2026, in the Ophthalmology Futures Forums taking place September 30, 2026,in Vienna.
プレゼンテーションの詳細：
Ophthalmology Futures Forums – Retina Forum 2026
Company Presentation
プレゼンター： Samarendra Mohanty, PhD, Co-Founder, President, and Chief Scientific Officer
日時： Wednesday, September 30, 2026, 17:50 PM CEST
位置： Imperial Riding School, Vienna
Panel 8: Geographic Atrophy & Intermediate AMD Therapeutics: Regional Evolution of a Global Business
パネリスト： サミュエル・バローネ医学博士、最高医療責任者
日時： Wednesday, September 30, 2026, 18:20 PM CEST
位置： Imperial Riding School, Vienna
26番目 ユーレティナ会議
プレゼンテーションタイトル: Vision Improvement in Macular Degeneration with Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 Randomized, Controlled Trial
プレゼンター： Jordi Mones, MD, PhD, Director, Institut de la Màcula, Barcelona, and member of the Nanoscope Visionary Advisory Committee
日時： Sunday, October 4, 2026, 10:51 AM CEST
セッション： Free Paper 42 – AMD/CSC
位置： Free Paper Forum 1
Poster Presentation: Optogenetic REMAIN 4-Year Study Data: Lasting Vision Improvement with MCO-010 in the RESTORE Phase 2b/3 Trial for Retinitis Pigmentosa
プレゼンター： Benjamin Bakall, MD, PhD, -Director for Clinical Research, Associated Retina Consultants, Phoenix, Arizona, and Assistant Professor, University of Arizona College of Medicine, Phoenix, Arizona
日付： Thursday, October 1, 2026
セッション： Inherited Retinal Diseases ePosters (RETINA26-1615)
位置： Poster Hub
These presentations, together with the Company’s corporate update on FDA acceptance of the BLA for MOGENRY® at the Ophthalmology Futures Forums Retina Forum, highlight the breadth of Nanoscope’s optogenetic pipeline, spanning the first direct-to-Phase 2 randomized, controlled trial of sonpiretigene isteparvovec in macular degeneration, and continued 4-year durability data from the RESTORE Phase 2b/3 trial in retinitis pigmentosa.
MOGENRY®（ソンピレチゲン・イステパルボベック；MCO-010）について
Nanoscope’s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope’s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY® is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope’s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY® makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY® does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.
ナノスコープ・セラピューティクスについて
ナノスコープ・セラピューティクスは、網膜変性疾患により失明した数百万人の患者のために、疾患の種類を問わず視力を回復させる光遺伝学的治療法を開発しています。網膜色素変性症（RP）を対象とした多施設共同無作為化二重盲検プラセボ対照臨床試験であるRESTORE第2b/3相試験で良好な結果が得られたことを受け、NCT04945772), the FDA has accepted and filed the Company’s BLA for MOGENRY®. If approved, MOGENRY® has the potential to become the standard of care for patients with RP, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126）であり、2026年に第3相登録試験を開始する予定です。MCO-010は、RPとSDの両方でFDAのファストトラックおよびオーファンドラッグ指定を受けており、SDについてはRMAT指定も受けています。また、非症候性および症候性の桿体および錐体優位性ジストロフィー、ならびに黄斑ジストロフィーを対象としたEMAのオーファン指定も受けています。MCO-010は、日本では遺伝性網膜ジストロフィー（IRD）の先駆け指定およびオーファン指定を受けており、サウジアラビアではIRDのオーファン指定を受けています。地理的萎縮症に対するMCOの第2相プログラムは2026年に開始される予定であり、IND準備中の他のプログラムにはレーバー先天性黒内障（LCA）が含まれます。.
接触：
ナノスコープ・セラピューティクス社
(817) 857-1186
PR@nanostherapeutics.com
出典 ナノスコープ・セラピューティクス